Literature DB >> 17251418

Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation.

Joseph F Cheer1, Kate M Wassum, Leslie A Sombers, Michael L A V Heien, Jennifer L Ariansen, Brandon J Aragona, Paul E M Phillips, R Mark Wightman.   

Abstract

Transient surges of dopamine in the nucleus accumbens are associated with drug seeking. Using a voltammetric sensor with high temporal and spatial resolution, we demonstrate differences in the temporal profile of dopamine concentration transients caused by acute doses of nicotine, ethanol, and cocaine in the nucleus accumbens shell of freely moving rats. Despite differential release dynamics, all drug effects are uniformly inhibited by administration of rimonabant, a cannabinoid receptor (CB1) antagonist, suggesting that an increase in endocannabinoid tone facilitates the effects of commonly abused drugs on subsecond dopamine release. These time-resolved chemical measurements provide unique insight into the neurobiological effectiveness of rimonabant in treating addictive disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251418      PMCID: PMC6672925          DOI: 10.1523/JNEUROSCI.4152-06.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  165 in total

1.  Differentiating the rapid actions of cocaine.

Authors:  Roy A Wise; Eugene A Kiyatkin
Journal:  Nat Rev Neurosci       Date:  2011-06-02       Impact factor: 34.870

2.  The regional specificity of rapid actions of cocaine.

Authors:  Brandon J Aragona
Journal:  Nat Rev Neurosci       Date:  2011-10-05       Impact factor: 34.870

3.  Methamphetamine-induced dopamine terminal deficits in the nucleus accumbens are exacerbated by reward-associated cues and attenuated by CB1 receptor antagonism.

Authors:  Gabriel C Loewinger; Michael V Beckert; Hugo A Tejeda; Joseph F Cheer
Journal:  Neuropharmacology       Date:  2012-01-25       Impact factor: 5.250

Review 4.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

5.  Selective breeding for high alcohol preference is associated with increased sensitivity to cannabinoid reward within the nucleus accumbens shell.

Authors:  Sheketha R Hauser; Simon N Katner; Robert A Waeiss; William A Truitt; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Pharmacol Biochem Behav       Date:  2020-07-23       Impact factor: 3.533

6.  Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum.

Authors:  Erik B Oleson; Michael V Beckert; Joshua T Morra; Carien S Lansink; Roger Cachope; Rehab A Abdullah; Amy L Loriaux; Dustin Schetters; Tommy Pattij; Mitchell F Roitman; Aron H Lichtman; Joseph F Cheer
Journal:  Neuron       Date:  2012-01-26       Impact factor: 17.173

Review 7.  A role for phasic dopamine release within the nucleus accumbens in encoding aversion: a review of the neurochemical literature.

Authors:  Jennifer M Wenzel; Noah A Rauscher; Joseph F Cheer; Erik B Oleson
Journal:  ACS Chem Neurosci       Date:  2014-12-24       Impact factor: 4.418

8.  Increased phasic dopamine signaling in the mesolimbic pathway during social defeat in rats.

Authors:  K K Anstrom; K A Miczek; E A Budygin
Journal:  Neuroscience       Date:  2009-03-17       Impact factor: 3.590

9.  Central cannabinoid 1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area.

Authors:  Alex Villanueva; Sertac M Yilmaz; William R Millington; Rodolfo A Cutrera; David G Stouffer; Loren H Parsons; Joseph F Cheer; Carlos Feleder
Journal:  Shock       Date:  2009-12       Impact factor: 3.454

10.  Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides.

Authors:  K Yaragudri Vinod; Suham A Kassir; Basalingappa L Hungund; Thomas B Cooper; J John Mann; Victoria Arango
Journal:  J Psychiatr Res       Date:  2009-12-16       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.